Report of Foreign Issuer (6-k)
October 16 2017 - 1:44PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
16 October
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the '
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
75.595
(personal contribution)
|
|
£15.275
|
187.204
(personal contribution)
|
|
£15.275
|
203.821
(personal contribution)
|
|
£15.275
|
75.595
(personal contribution)
|
|
£15.275
|
187.191
(personal contribution)
|
|
£15.275
|
203.809
(personal contribution)
|
|
£15.275
|
75.595
(matching shares)
|
|
£15.275
|
187.204
(matching shares)
|
|
£15.275
|
203.821
(matching shares)
|
|
£15.275
|
75.595
(matching shares)
|
|
£15.275
|
187.191
(matching shares)
|
|
£15.275
|
203.809
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,866.43
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
55.361
(personal contribution)
|
|
£15.275
|
127.190
(personal contribution)
|
|
£15.275
|
106.128
(personal contribution)
|
|
£15.275
|
55.361
(personal contribution)
|
|
£15.275
|
106.115
(personal contribution)
|
|
£15.275
|
55.361
(matching shares)
|
|
£15.275
|
127.19
(matching shares)
|
|
£15.275
|
106.128
(matching shares)
|
|
£15.275
|
55.361
(matching shares)
|
|
£15.275
|
106.115
(matching contribution)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
900.310
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr L Debruyne
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
178.377
(personal contribution)
|
|
£15.275
|
178.365
(personal contribution)
|
|
£15.275
|
178.377
(matching shares)
|
|
£15.275
|
178.365
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
713.484
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
105.590
(personal contribution)
|
|
£15.275
|
247.218
(personal contribution)
|
|
£15.275
|
185.166
(personal contribution)
|
|
£15.275
|
105.576
(personal contribution)
|
|
£15.275
|
247.205
(personal contribution)
|
|
£15.275
|
185.166
(personal contribution)
|
|
£15.275
|
105.590
(matching shares)
|
|
£15.275
|
247.218
(matching shares)
|
|
£15.275
|
185.166
(matching shares)
|
|
£15.275
|
105.576
(matching shares)
|
|
£15.275
|
247.205
(matching shares)
|
|
£15.275
|
185.166
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
2,151.842
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
38.762
(personal contribution)
|
|
£15.275
|
91.407
(personal contribution)
|
|
£15.275
|
67.081
(personal contribution)
|
|
£15.275
|
38.762
(personal contribution)
|
|
£15.275
|
91.407
(personal contribution)
|
|
£15.275
|
67.068
(personal contribution)
|
|
£15.275
|
38.762
(matching shares)
|
|
£15.275
|
91.407
(matching shares)
|
|
£15.275
|
67.081
(matching shares)
|
|
£15.275
|
38.762
(matching shares)
|
|
£15.275
|
91.407
(matching shares)
|
|
£15.275
|
67.068
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
788.974
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 12 October 2017 on ADSs held
in the Company's 2009 Deferred Annual Bonus Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.020
|
75.963
(personal contribution)
|
|
$41.020
|
75.963
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
151.926
$
41.020
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
62.115
(personal contribution)
|
|
£15.275
|
116.331
(personal contribution)
|
|
£15.275
|
84.422
(personal contribution)
|
|
£15.275
|
62.115
(personal contribution)
|
|
£15.275
|
116.331
(personal contribution)
|
|
£15.275
|
84.409
(personal contribution)
|
|
£15.275
|
62.115
(matching shares)
|
|
£15.275
|
116.331
(matching shares)
|
|
£15.275
|
84.422
(matching shares)
|
|
£15.275
|
62.115
(matching shares)
|
|
£15.275
|
116.331
(matching shares)
|
|
£15.275
|
84.409
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,051.446
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
83.607
(personal contribution)
|
|
£15.275
|
170.189
(personal contribution)
|
|
£15.275
|
127.067
(personal contribution)
|
|
£15.275
|
83.594
(personal contribution)
|
|
£15.275
|
170.189
(personal contribution)
|
|
£15.275
|
127.067
(personal contribution)
|
|
£15.275
|
83.607
(matching shares)
|
|
£15.275
|
170.189
(matching shares)
|
|
£15.275
|
127.067
(matching shares)
|
|
£15.275
|
83.594
(matching shares)
|
|
£15.275
|
170.189
(matching shares)
|
|
£15.275
|
127.067
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,523.426
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
56.787
(personal contribution)
|
|
£15.275
|
104.127
(personal contribution)
|
|
£15.275
|
79.994
(personal contribution)
|
|
£15.275
|
56.787
(matching shares)
|
|
£15.275
|
104.127
(matching shares)
|
|
£15.275
|
79.994
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
481.816
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D E Troy
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 12 October 2017 on ADSs held
in the Company's 2009 Deferred Annual Bonus Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.020
|
43.227
(personal contribution)
|
|
$41.020
|
97.329
(personal contribution)
|
|
$41.020
|
80.611
(personal contribution)
|
|
$41.020
|
43.227
(personal contribution)
|
|
$41.020
|
97.329
(personal contribution)
|
|
$41.020
|
80.599
(personal contribution)
|
|
$41.020
|
43.227
(matching shares)
|
|
$41.020
|
97.329
(matching shares)
|
|
$41.020
|
80.611
(matching shares)
|
|
$41.020
|
43.227
(matching shares)
|
|
$41.020
|
97.329
(matching shares)
|
|
$41.020
|
80.599
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
884.644
$41.020
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President,
R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.275
|
123.070
(personal contribution)
|
|
£15.275
|
200.197
(personal contribution)
|
|
£15.275
|
138.016
(personal contribution)
|
|
£15.275
|
123.070
(personal contribution)
|
|
£15.275
|
200.197
(personal contribution)
|
|
£15.275
|
138.016
(personal contribution)
|
|
£15.275
|
123.070
(matching shares)
|
|
£15.275
|
200.197
(matching shares)
|
|
£15.275
|
138.016
(matching shares)
|
|
£15.275
|
123.070
(matching shares)
|
|
£15.275
|
200.197
(matching shares)
|
|
£15.275
|
138.016
(matching shares)
|
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
1,845.132
£15.275
|
|
e)
|
Date
of the transaction
|
2017-10-12
|
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
16, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
